Table 3.

PASS cutpoints with 2 methodological approaches for health-related quality of life and health status measures after 3 months of DMARD treatment in patients with RA, PsA, and AS.

75% Sensitivity Cutpoint80% Specificity CutpointReceiver-operating Characteristic (ROC) Curves
Area Under the Curve95% CI
EQ-5D
  RA0.620.690.800.77–0.83
  PsA0.690.730.780.72–0.84
  AS0.690.690.820.77–0.87
SF-6D
  RA0.600.650.790.78–0.81
  PsA0.600.650.800.76–0.82
  AS0.640.660.850.81–0.88
Patient global VAS
  RA37310.820.81–0.84
  PsA38300.800.77–0.83
  AS32280.840.81–0.88
Pain VAS
  RA36270.790.78–0.81
  PsA35250.780.75–0.81
  AS28260.850.82–0.88
MHAQ
  RA0.630.330.750.73–0.77
  PsA0.500.140.750.71–0.78
  AS0.500.130.760.72–0.80
  • PASS: Patient Acceptable Symptom State; DMARD: disease-modifying antirheumatic drug; RA: rheumatoid arthritis; PsA: psoriatic arthritis; AS: ankylosing spondylitis; MHAQ: Modified Health Assessment Questionnaire; VAS: visual analog scale; EQ-5D: EuroQol-5 Dimensions; SF-6D: Short-Form-6 Dimensions.